Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
Jeong A Park(Memorial Sloan Kettering Cancer Center), Nai‐Kong V. Cheung(Memorial Sloan Kettering Cancer Center)
Cited by 47
Related Papers
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
|Journal of Hematology & Oncology|2020|86